Immunohistochemistry/Immunofluorescence (IHC/IF) Analysis Services
Immunohistochemistry and immunofluorescence stand as the cornerstone techniques for visualizing protein expression and cellular architecture within intact tissue specimens, bridging molecular data with morphological context. At Alfa Cytolog, we transform complex tissue biology into actionable insights through precision IHC/IF analysis tailored to your preclinical oncology drug development pipeline.
Overview of IHC/IF Technologies
Immunohistochemistry (IHC) and immunofluorescence (IF) are antibody-based molecular assays that enable the detection and localization of specific proteins within tissue sections at cellular and subcellular resolution. IHC utilizes enzyme-chromogen reactions—most commonly horseradish peroxidase with 3,3'-diaminobenzidine (DAB)—to produce stable, colorimetric signals that can be visualized under brightfield microscopy. This approach preserves tissue architecture and cytologic detail, making it the gold standard for experimental pathology and routine protein expression analysis in preclinical research. In contrast, IF employs fluorophore-conjugated antibodies that emit distinct spectral signals, allowing researchers to observe dynamic protein distribution, co-localization patterns, and multiplexed target detection through fluorescence microscopy. Both techniques are indispensable across experimental histopathology, oncology, neuroscience, and immuno-oncology research, where understanding spatial protein distribution is paramount.
Fig 1. Immunohistochemistry (IHC) analyses of hepatocellular carcinoma (HCC) samples and corresponding patient-derived organoids (PDOs). (Lo Re, Oriana, et al., 2026)
The distinction between these two modalities extends beyond detection chemistry. IHC offers permanent, light-insensitive preparations ideal for long-term archival and low-power screening of large tissue fields, while IF delivers superior sensitivity, quantitative signal output, and the unique capacity for multicolor labeling—enabling simultaneous visualization of three or more biomarkers within a single section. Advances in tyramide signal amplification (TSA) and spectral unmixing technologies have further expanded the multiplexing capabilities of IF, allowing comprehensive profiling of the tumor immune microenvironment (TIME) without consuming multiple tissue sections. As drug development increasingly pivots toward immuno-oncology and targeted therapies, the choice between chromogenic IHC and fluorescent IF—or their strategic combination—has become a critical decision point in translational research and preclinical biomarker discovery.
Multiplex IHC/IF and Spatial Analysis in Tumor Microenvironment Profiling
| Platform / Technology |
Key Features |
Primary Applications |
| Chromogenic IHC (DAB) |
Stable, permanent stains; brightfield microscopy compatible; ideal for archival and experimental review |
Routine pathology assessment; single/dual biomarker evaluation; tissue morphology preservation in preclinical models |
| Fluorescent IF (Direct/Indirect) |
Multicolor detection; co-localization analysis; subcellular resolution; quantitative signal output |
Protein interaction studies; dynamic localization; multi-target screening on single sections |
| TSA-Based mIHC/mIF |
Signal amplification up to 100–1000×; sequential staining with antibody stripping; same-species antibody compatibility |
Low-abundance target detection; 6–8-plex panels; tumor immune microenvironment mapping |
| Opal / Phenoptics™ |
Spectral unmixing; autofluorescence subtraction; integrated acquisition and analysis workflow |
Immuno-oncology biomarker panels; spatial phenotyping; tertiary lymphoid structure analysis |
| Digital Image Analysis (HALO, QuPath) |
Whole-slide quantification; batch processing; cell phenotyping; spatial statistics and proximity analysis |
High-throughput biomarker scoring; immune cell infiltration quantification; preclinical study data support |
| Mass Cytometry Imaging |
Highest multiplexing capacity (30+ parameters); single-cell resolution in tissue context |
Deep immune profiling; signaling pathway mapping; spatial proteomics research |
Our Services
Alfa Cytolog delivers end-to-end IHC/IF analysis services designed specifically for preclinical oncology studies and translational drug development. From chromogenic single-marker assays to advanced multiplex immunofluorescence panels, our team supports every phase of your preclinical project—from assay development and antibody validation through high-resolution imaging and quantitative digital pathology. Whether you are profiling immune checkpoint expression, characterizing tumor-infiltrating lymphocytes, or validating pharmacodynamic biomarkers in in vivo xenograft and in vitro models, we provide the technical depth and scientific rigor required to advance your therapeutic candidates with confidence.
Our IHC/IF Analysis Services
Chromogenic IHC Staining
Single-marker and dual-marker chromogenic IHC on FFPE and frozen tissue sections, optimized for tumor models, normal tissue cross-reactivity studies, and biomarker expression scoring. We customize antibody concentrations, antigen retrieval conditions, and counterstain protocols to ensure robust, reproducible staining with minimal background.
Immunofluorescence (IF) Staining
Direct and indirect IF services using Alexa Fluor, Cy-dye, and DAPI nuclear counterstains for subcellular localization, co-expression analysis, and dynamic protein tracking. Compatible with both tissue sections and cell culture specimens from in vivo and in vitro experiments.
Assay Development & Validation
Tailored assay development from antibody selection and epitope mapping through protocol optimization, precision testing, and specificity verification. Final protocols are documented in detailed standard operating procedures with locked conditions.
Digital Image Analysis & Quantification
Whole-slide scanning, multispectral image acquisition, and computational analysis using advanced software platforms. Services include cell counting, biomarker expression scoring, immune infiltration quantification, and spatial proximity measurements.
Tissue Cross-Reactivity (TCR) Studies
Systematic screening of therapeutic antibody binding across normal human and animal tissue panels using IHC/IF, supporting target validation and off-target liability assessment early in development.
Pharmacodynamic (PD) Biomarker Analysis
Quantitative assessment of target engagement, pathway modulation, and treatment-induced phenotypic changes in tumor and surrogate tissues from preclinical efficacy studies.
Workflow of IHC/IF Analysis Services
Each IHC/IF project at Alfa Cytolog follows a structured, milestone-driven workflow designed to ensure scientific integrity, reproducibility, and timely delivery. From initial consultation through final reporting, our process integrates quality control checkpoints at every stage.
1. Project Consultation & Experimental Design: Our scientists collaborate with you to define study objectives, select appropriate markers, determine IHC versus IF modality, and establish the optimal multiplexing strategy based on your tissue type and research questions.
2. Sample Receipt & Processing: Tissue specimens undergo standardized fixation, embedding, and sectioning (typically 4–5 μm). Fresh tissues are immediately preserved to prevent antigen degradation, while FFPE blocks are sectioned under rigorous quality controls.
3. Antibody Selection & Validation: Primary antibodies are rigorously screened for specificity, affinity, and optimal working dilution. Positive and negative control tissues are incorporated to confirm assay performance and rule out non-specific binding.
4. Protocol Optimization: Staining parameters—including antigen retrieval method, blocking conditions, antibody incubation time and temperature, and chromogen/fluorophore selection—are systematically optimized for each target and tissue type.
5. Staining Execution: Automated staining platforms ensure reproducibility across batches. Single, dual, or multiplex staining is performed with real-time quality monitoring.
6. Imaging & Digital Analysis: High-resolution whole-slide scanning or multispectral image acquisition is conducted. Computational tools are applied for cell phenotyping, biomarker quantification, and spatial statistics.
7. Pathologist Review & Reporting: Trained pathologists review stained slides for morphological accuracy. A comprehensive report with representative images, quantitative data, and methodological details is delivered.
Why Choose Alfa Cytolog?
Partnering with Alfa Cytolog means gaining access to a team that understands the scientific and operational demands of preclinical oncology research. We combine technical precision with flexible project management to accelerate your path from target validation to IND-enabling studies.
- Deep oncology focus with specialized expertise in tumor models, immune profiling, and biomarker strategies
- Custom assay development tailored to your target, tissue type, and downstream analysis requirements
- Advanced multiplexing capabilities enabling simultaneous detection of multiple immune and tumor markers
- Integrated digital pathology and quantitative image analysis for robust, reproducible data generation
- Seamless compatibility with in vivo xenograft and in vitro sample workflows for end-to-end preclinical study support
- Rigorous quality controls including positive/negative controls, batch consistency checks, and pathologist review
- Rapid turnaround times with transparent communication and milestone-based project tracking
- Comprehensive reporting with publication-ready images, raw data files, and detailed methodology
Contact Us
Ready to advance your preclinical oncology program with precision IHC/IF analysis? Reach out to us today to discuss your project requirements, request a quote, or schedule a consultation with our scientific team. Whether you need a single-marker screen or a complex multiplex panel, Alfa Cytolog is here to deliver the data quality and scientific insight your drug development pipeline demands.
Reference
- Lo Re, Oriana, et al. "Establishment of Patient-Derived Organoids from Hepatocellular Carcinoma: Preliminary Data on Yield, Histopathological Concordance, and Methodological Challenges." Cells 15.2 (2026): 125.
For research use only. Not intended for any clinical use.
